Sign Out
SITAGLIPTIN + METFORMIN HCl (JANUMET) is contraindicated in patients with: Severe renal impairment, (eGFR < 30 mL/min/1.73 m2) (see Monitoring of renal function under Precautions).
2. Known hypersensitivity to sitagliptin phosphate, metformin hydrochloride or any other component of SITAGLIPTIN + METFORMIN HCl (JANUMET) (see Sitagliptin phosphate, Hypersensitivity Reactions under Precautions and Postmarketing Experience under Adverse Reactions).
3. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
SITAGLIPTIN + METFORMIN HCl (JANUMET) should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function (see Metformin hydrochloride under Precautions).
